Please assess the completion status of the following clinical trial:

Trial Title: Variation in Sulphonylurea Response in Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Age \>35 and \< 70~* Age of diabetes diagnosis \>35 and \<70~* White European~* Pre-SU HbA1c \<=10%~* HbA1c (on treatment) \<= 9%~* No myocardial infarction or Acute coronary syndrome in previous year~* No stroke or transient ischaemic attack in previous year~* No or stable (background) retinopathy (no unscheduled laser treatment in the last 6 months)~* eGFR \> 60mls/min~* No Proteinuria \>30mg/dl on multistix 10SG~* No active foot ulceration or infection~* Liver ALT ≤ twice the upper limit of the reference range~* Contactable by telephone~Exclusion Criteria:~* Type 1 diabetes~* HbA1c \>10% prior to commencing SU~* HbA1c\>9% on SU treatment~* Recent MI or Stroke within last 12 months~* Pre-proliferative or proliferative retinopathy~* eGFR\<60 ml/min~* Proteinuria \>30mg/dl on multistix 10SG~* Active foot ulceration or infection~* Liver ALT \> twice the upper limit of the reference range~* Female planning to conceive within the study period~* Any other significant medical reason for exclusion as determined by the investigator

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Withdrawal of sulphonylurea for 6 weeks, then re-introduction for 6 weeks, assessed by fasting glucose and HbA1c

Based on this trial design, predict the completion outcome and termination type (if applicable).